Eyenovia (NASDAQ:EYEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Eyenovia (NASDAQ:EYEN) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the prior year, the company earned ($0.18) EPS.

Eyenovia Trading Down 16.5 %

Shares of NASDAQ:EYEN opened at $0.34 on Friday. The stock’s 50-day simple moving average is $0.50 and its two-hundred day simple moving average is $0.71. Eyenovia has a 52-week low of $0.33 and a 52-week high of $2.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.27 and a current ratio of 0.74. The stock has a market capitalization of $21.79 million, a price-to-earnings ratio of -0.47 and a beta of 1.75.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Eyenovia in a report on Wednesday. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a report on Friday, August 30th.

Insider Buying and Selling

In other news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction on Monday, August 26th. The shares were acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at $47,268.39. This trade represents a 151.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.10% of the stock is currently owned by insiders.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.